Physician profile
April Hansen
NPI 1649984105
$2,161.89
in general payments reported to CMS, 2019-2025
21 companies · $937 in 2025
The $937 reported for 2025 was more than what 95% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $630 · 2024: $594 · 2025: $937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,063 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,062.89 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $620.95 | 2023-2025 | Tivdak |
| Merck Sharp & Dohme LLC | $304.26 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $218.16 | 2023-2025 | Lynparza, Calquence |
| Glaxosmithkline, LLC. | $211.97 | 2023-2025 | Jemperli, Zejula |
| Novartis Pharmaceuticals Corporation | $169.98 | 2023-2024 | |
| Emd Serono, INC. | $89.28 | 2023-2024 | Bavencio |
| Blueprint Medicines Corporation | $67.67 | 2023 | Gavreto |
| Regeneron Healthcare Solutions, INC. | $62.75 | 2023-2025 | Libtayo |
| Eisai INC. | $61.13 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $52.06 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Napo Pharmaceuticals INC | $42.35 | 2025 | Gelclair Concentrated Oral Gel |
| Stemline Therapeutics INC. | $42.28 | 2025 | Orserdu |
| Foundation Medicine, INC. | $31.04 | 2023 | |
| Janssen Biotech, INC. | $29.64 | 2023 | |
| Jazz Pharmaceuticals INC. | $26.32 | 2023 | Zepzelca |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $25.34 | 2024 | Ultomiris |
| Kite Pharma, INC. | $23.57 | 2025 | Yescarta |
| Bayer Healthcare Pharmaceuticals INC. | $23.04 | 2024 | |
| Chiesi USA, INC. | $21.56 | 2024 | Ferriprox |
| Syndax Pharmaceuticals, INC. | $20.59 | 2025 | Revuforj |
| Daiichi Sankyo INC. | $17.95 | 2025 | Enhertu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.